Brought to you by 
AstraZeneca divests Myalept to Aegerion
03 Jan 2022
Executive Summary
In order to focus on its core therapy areas, AstraZeneca PLC divested Myalept (metreleptin injection) to Aegerion Pharmaceuticals Inc., which will pay $325mm cash.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca divests Myalept to Aegerion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice